Trial Profile

Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rosuvastatin (Primary)
Indications Adult respiratory distress syndrome; Systemic inflammatory response syndrome
Focus Therapeutic Use
Acronyms SAILS

Most Recent Events

10 Jun 2021 Results (n=568) of secondary analysis of SAILS-ALTOS trial evaluating if subphenotype status was associated with differences in physical, mental health and cognitive outcomes, based on a prior prospective evaluation of SAILS patients over 6-month and 12-month follow-up published in the Thorax
20 May 2020 Results of secondary analysis presented at the 116th International Conference of the American Thoracic Society
17 Aug 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com